[go: up one dir, main page]

MX2023010941A - Compuestos antibacterianos. - Google Patents

Compuestos antibacterianos.

Info

Publication number
MX2023010941A
MX2023010941A MX2023010941A MX2023010941A MX2023010941A MX 2023010941 A MX2023010941 A MX 2023010941A MX 2023010941 A MX2023010941 A MX 2023010941A MX 2023010941 A MX2023010941 A MX 2023010941A MX 2023010941 A MX2023010941 A MX 2023010941A
Authority
MX
Mexico
Prior art keywords
antibacterial compounds
compounds
antibacterial
tuberculosis
medicaments
Prior art date
Application number
MX2023010941A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Jérôme Émile Georges Guillemont
Magali Madeleine Simone Motte
Dirk Antonie Lamprecht
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2023010941A publication Critical patent/MX2023010941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con los siguientes compuestos (I), en donde los enteros son como se definen en la descripción, y donde los compuestos pueden ser útiles como medicamentos, por ejemplo para su uso en el tratamiento de la tuberculosis.
MX2023010941A 2021-03-17 2022-03-16 Compuestos antibacterianos. MX2023010941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21163042 2021-03-17
PCT/EP2022/056774 WO2022194906A1 (en) 2021-03-17 2022-03-16 Antibacterial compounds

Publications (1)

Publication Number Publication Date
MX2023010941A true MX2023010941A (es) 2023-11-28

Family

ID=74947094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010941A MX2023010941A (es) 2021-03-17 2022-03-16 Compuestos antibacterianos.

Country Status (10)

Country Link
US (1) US20240182495A1 (es)
EP (1) EP4308579A1 (es)
JP (1) JP2024509998A (es)
KR (1) KR20230157445A (es)
CN (1) CN117440958A (es)
AU (1) AU2022236404A1 (es)
BR (1) BR112023018654A2 (es)
CA (1) CA3212074A1 (es)
MX (1) MX2023010941A (es)
WO (1) WO2022194906A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3234515A1 (en) * 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) * 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) * 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2421A (en) 2002-07-25 2012-06-08 Janssen Pharmaceutica Nl Quinoline derivatives and their use as mycobacterial inhibitors.
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
CN102428087B (zh) * 2009-04-16 2015-06-17 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的咪唑并吡嗪类化合物
ES2572387T3 (es) * 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
MX339937B (es) 2011-09-01 2016-06-17 Novartis Ag * Compuestos y composiciones como inhibidores de la quinasa c-kit.
RU2696278C2 (ru) * 2012-07-18 2019-08-01 Юниверсити Оф Нотр Дам Дю Лак 5,5-гетероароматические противоинфекционные соединения
ES2883565T3 (es) 2013-08-02 2021-12-09 Pasteur Institut Korea Compuestos antiinfecciosos
EP3316968A1 (en) 2015-07-02 2018-05-09 Janssen Sciences Ireland UC Antibacterial compounds
EA201990044A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Гетероциклические соединения в качестве антибактериальных средств
AU2017286368B2 (en) * 2016-06-16 2021-02-25 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials

Also Published As

Publication number Publication date
WO2022194906A1 (en) 2022-09-22
JP2024509998A (ja) 2024-03-05
CN117440958A (zh) 2024-01-23
CA3212074A1 (en) 2022-09-22
US20240182495A1 (en) 2024-06-06
AU2022236404A1 (en) 2023-11-02
KR20230157445A (ko) 2023-11-16
EP4308579A1 (en) 2024-01-24
BR112023018654A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
MX2023010941A (es) Compuestos antibacterianos.
ZA201708692B (en) Antibacterial compounds
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
EP4516301A3 (en) Nitrile-containing compounds for use as medicaments
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
MX2023010948A (es) Compuestos antibacterianos.
PH12023550161A1 (en) Pharmaceutical composition and use thereof
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
PH12021500034A1 (en) Compounds useful in hiv therapy
PH12022550130A1 (en) Enzyme inhibitors
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2020011817A (es) Metodos para tratar el linfoma.
WO2018094023A3 (en) Cyclic dipeptides and wound healing
PH12022550118A1 (en) Enzyme inhibitors
ZA202006612B (en) Antibacterial compounds
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
MX2023010947A (es) Compuestos antibacterianos.
WO2023285654A3 (en) Compounds for the treatment of covid-19
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing